Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710125 · ClinicalTrials.gov registry record · Phase 1
Safety Study of GPX-150 in Patients With Solid Tumors
A Phase 1 study, sponsored by Gem Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00710125 is a Phase 1 study that has completed, run by Gem Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00710125, a Phase 1 study, has completed, sponsored by Gem Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Interventions
- DRUG GPX-150 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710125
The ClinicalTrials.gov registry entry for NCT00710125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gem Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GPX-150 for Injection is the first listed.
NCT00710125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00710125 about?
NCT00710125 is a clinical study titled "Safety Study of GPX-150 in Patients With Solid Tumors". This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be a...
What is the current status of trial NCT00710125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00710125?
The interventions under investigation include: GPX-150 for Injection (DRUG).
Who is sponsoring clinical trial NCT00710125?
This trial is sponsored by Gem Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.